1. Scrip
  2. >>R&D

Paratek Sees Broad Potential For Omadacycline After Second Phase III Win

 
• By Mandy Jackson

Paratek Pharmaceuticals will seek US FDA approval for omadacycline in early 2018 based on a second successful Phase III study for its antibiotic. The company believes the drug has broad potential against multiple pathogens and across multiple patient populations.

Antibiotic resistant bacteria closeup biofilm

Paratek Pharmaceuticals Inc. believes its antibiotic omadacycline, which it will submit for US FDA approval in the first quarter of 2018, has broad potential against a variety of pathogens and patient populations based on the drug's second successful Phase III clinical trial.

Boston-based Paratek reported on April 3 that its broad spectrum oral and intravenous antibiotic proved its non-inferiority to moxifloxacin in the treatment of community-acquired bacterial pneumonia (CABP), including the Phase III OPTIC trial's separate primary endpoints for FDA and European Medicines Agency (EMA) approvals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.